Business
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024\nCompleting enrollment of the originally-targeted 70 patients in the Phase 2b/3 trial of NRX-101 in Treatment Resistant Bipolar Depression; enrollment to continue through November to increase study power; last patient visit expected in January. Data expected to be released shortly thereafterOpened the Investigational New Drug application (IND) with Food and Drug Administration (FDA) to treat chronic pain with NRX-101. Awaiting results of 200-person DOD-funded trial in treatment of chronic pain with D-cycloserine (DCS) from Northwestern University in the near termReceived data from randomized, controlled trials demonstrating safety and efficacy of IV ketamine in treating suicidal depression, and established manufacturing partnership to enable filing of a New Drug Application (NDA) for what would be the first FDA-approved presentation of IV ketamine for this purpose in 1Q24. Planning a newly capitalized, publicly traded, ketamine-focused entity that will be owned by NRx, current NRx shareholders, and new investors; Term Sheet received from prospective anchor investorSubmitted an IND application with FDA to treat complicated Urinary Tract Infection (cUTI) with NRX-101; Qualified Infectious Disease Product (QIDP) request response expected around year-end 2023.Management to address evidence of naked shorting of NRx securitiesManagement to host a conference call tomorrow, November 14, 2023, at 4:30 PM ETRADNOR, Pa., Nov. 13, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended September 30, 2023 and provided a business update. Given the volume of information discussed this quarter, we have issued this release in advance of our conference call to allow investors additional time to review.\n\n \n \n \n \n \n \n\n \n\"The third quarter represents a potential turning point for our company, as we are approaching our clinical trial enrollment goals for our partnered foundation product NRX-101, while opening new clinical initiatives in chronic pain, urinary tract infection, and NRX-100 for suicidal depression,\" said Stephen Willard, J.D., Chief Executive Officer and Director of N...